Moody National Bank Trust Division acquired a new stake in Biogen Inc. (NASDAQ:BIIB – Get Rating) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,372 shares of the biotechnology company’s stock, valued at approximately $280,000.
Several other large investors have also bought and sold shares of BIIB. Curi Wealth Management LLC lifted its holdings in Biogen by 476.2% in the first quarter. Curi Wealth Management LLC now owns 121 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 100 shares during the period. J.W. Cole Advisors Inc. acquired a new stake in Biogen in the first quarter worth $26,000. Tcwp LLC acquired a new stake in Biogen in the first quarter worth $33,000. Pflug Koory LLC raised its holdings in Biogen by 88.2% in the first quarter. Pflug Koory LLC now owns 160 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 75 shares during the period. Finally, Compagnie Lombard Odier SCmA acquired a new stake in Biogen in the first quarter worth $42,000. 83.45% of the stock is currently owned by institutional investors and hedge funds.
Biogen Stock Performance
Shares of BIIB opened at $204.20 on Wednesday. The firm has a 50-day moving average of $209.88 and a 200-day moving average of $207.14. Biogen Inc. has a one year low of $187.16 and a one year high of $304.21. The company has a market cap of $29.63 billion, a PE ratio of 14.56, a price-to-earnings-growth ratio of 0.95 and a beta of 0.43. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.94 and a quick ratio of 1.68.
Analyst Ratings Changes
Several equities research analysts have weighed in on the stock. Jefferies Financial Group reiterated a “buy” rating and issued a $300.00 target price on shares of Biogen in a report on Tuesday. Barclays cut their target price on shares of Biogen from $210.00 to $200.00 and set an “equal weight” rating on the stock in a report on Thursday, July 21st. Oppenheimer increased their target price on shares of Biogen from $225.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 18th. Needham & Company LLC lowered their price objective on shares of Biogen from $262.00 to $250.00 and set a “buy” rating for the company in a research report on Thursday, July 21st. Finally, StockNews.com raised shares of Biogen from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 27th. Thirteen analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.79.
Biogen Company Profile
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.
- Get a free copy of the StockNews.com research report on Biogen (BIIB)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.